+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Kidney Cancer Drugs Global Market Report 2021: COVID-19 Impact and Recovery to 2030

  • ID: 5351779
  • Report
  • June 2021
  • Region: Global
  • The Business Research Company

FEATURED COMPANIES

  • Abbott Laboratories
  • Aveo Pharmaceuticals
  • Eisai
  • Glaxosmithkline Plc
  • NeoGenomics Laboratories
  • Prometheus Laboratories
  • MORE
Kidney Cancer Drugs Global Market Report 2021: COVID-19 Impact and Recovery to 2030 provides strategists, marketers and senior management with the critical information they need to assess the global kidney cancer drugs market as it emerges from the COVID-19 shut down.

Reasons to Purchase
  • Gain a truly global perspective with the most comprehensive report available on this market covering 12+ geographies.
  • Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market research findings.
  • Benchmark performance against key competitors.
  • Utilize the relationships between key data sets for superior strategizing.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Description:

Where is the largest and fastest growing market for the kidney cancer drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The Kidney Cancer Drugs Market Global Report answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
  • The Market Characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, the impact of the COVID-19 virus and forecasting its recovery.
  • Market segmentations break down market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the impact and recovery trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope

Markets Covered:

1) By Type: Renal Cell Carcinoma (RCC); Transitional Cell Carcinoma (TCC) or Urothelial cell carcinoma (UCC)
2) By Product: Nexavar (Sorafenib); Sutent (Sunitinib); Afinitor (Everolimus); Votrient (Pazopanib); Avastin (Bevacizumab); Inlyta (Axitinib); Torisel (Temsirolimus); Proleukin (Aldesleukin); Others
3) By End Users: Hospitals; Clinics; Research Center; Others

Companies Mentioned: Bayer AG; Pfizer Inc; Novartis International AG; Exelixis; F. Hoffmann-La Roche Ag

Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA

Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time Series: Five years historic and ten years forecast.

Data Segmentations: Country and regional historic and forecast data, market share of competitors, market segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

This report will be delivered within 1-3 business days.

Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Abbott Laboratories
  • Aveo Pharmaceuticals
  • Eisai
  • Glaxosmithkline Plc
  • NeoGenomics Laboratories
  • Prometheus Laboratories
  • MORE
1. Executive Summary

2. Kidney Cancer Drugs Market Characteristics

3. Kidney Cancer Drugs Market Trends And Strategies

4. Impact Of COVID-19 On Kidney Cancer Drugs

5. Kidney Cancer Drugs Market Size And Growth
5.1. Global Kidney Cancer Drugs Historic Market, 2015-2020, $ Billion
5.1.1. Drivers Of The Market
5.1.2. Restraints On The Market
5.2. Global Kidney Cancer Drugs Forecast Market, 2020-2025F, 2030F, $ Billion
5.2.1. Drivers Of The Market
5.2.2. Restraints On the Market

6. Kidney Cancer Drugs Market Segmentation
6.1. Global Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Renal Cell Carcinoma (RCC)
  • Transitional Cell Carcinoma (TCC) or Urothelial cell carcinoma (UCC)
6.2. Global Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Nexavar (Sorafenib)
  • Sutent (Sunitinib)
  • Afinitor (Everolimus)
  • Votrient (Pazopanib)
  • Avastin (Bevacizumab)
  • Inlyta (Axitinib)
  • Torisel (Temsirolimus)
  • Proleukin (Aldesleukin)
  • Others
6.3. Global Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Hospitals
  • Clinics
  • Research Center
  • Others
7. Kidney Cancer Drugs Market Regional And Country Analysis
7.1. Global Kidney Cancer Drugs Market, Split By Region, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
7.2. Global Kidney Cancer Drugs Market, Split By Country, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

8. Asia-Pacific Kidney Cancer Drugs Market
8.1. Asia-Pacific Kidney Cancer Drugs Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
8.3. Asia-Pacific Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
8.4. Asia-Pacific Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

9. China Kidney Cancer Drugs Market
9.1. China Kidney Cancer Drugs Market Overview
9.2. China Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F,$ Billion
9.3. China Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F,$ Billion
9.4. China Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F,$ Billion

10. India Kidney Cancer Drugs Market
10.1. India Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
10.2. India Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
10.3. India Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

11. Japan Kidney Cancer Drugs Market
11.1. Japan Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
11.2. Japan Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
11.3. Japan Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

12. Australia Kidney Cancer Drugs Market
12.1. Australia Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
12.2. Australia Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
12.3. Australia Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

13. Indonesia Kidney Cancer Drugs Market
13.1. Indonesia Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
13.2. Indonesia Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
13.3. Indonesia Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

14. South Korea Kidney Cancer Drugs Market
14.1. South Korea Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
14.2. South Korea Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
14.3. South Korea Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

15. Western Europe Kidney Cancer Drugs Market
15.1. Western Europe Kidney Cancer Drugs Market Overview
15.2. Western Europe Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
15.3. Western Europe Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
15.4. Western Europe Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

16. UK Kidney Cancer Drugs Market
16.1. UK Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
16.2. UK Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
16.3. UK Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

17. Germany Kidney Cancer Drugs Market
17.1. Germany Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
17.2. Germany Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
17.3. Germany Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

18. France Kidney Cancer Drugs Market
18.1. France Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
18.2. France Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
18.3. France Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

19. Eastern Europe Kidney Cancer Drugs Market
19.1. Eastern Europe Kidney Cancer Drugs Market Overview
19.2. Eastern Europe Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
19.3. Eastern Europe Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
19.4. Eastern Europe Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

20. Russia Kidney Cancer Drugs Market
20.1. Russia Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
20.2. Russia Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
20.3. Russia Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

21. North America Kidney Cancer Drugs Market
21.1. North America Kidney Cancer Drugs Market Overview
21.2. North America Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
21.3. North America Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
21.4. North America Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

22. USA Kidney Cancer Drugs Market
22.1. USA Kidney Cancer Drugs Market Overview
22.2. USA Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
22.3. USA Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
22.4. USA Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

23. South America Kidney Cancer Drugs Market
23.1. South America Kidney Cancer Drugs Market Overview
23.2. South America Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
23.3. South America Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
23.4. South America Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

24. Brazil Kidney Cancer Drugs Market
24.1. Brazil Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
24.2. Brazil Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
24.3. Brazil Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

25. Middle East Kidney Cancer Drugs Market
25.1. Middle East Kidney Cancer Drugs Market Overview
25.2. Middle East Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
25.3. Middle East Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
25.4. Middle East Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

26. Africa Kidney Cancer Drugs Market
26.1. Africa Kidney Cancer Drugs Market Overview
26.2. Africa Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
26.3. Africa Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
26.4. Africa Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

27. Kidney Cancer Drugs Market Competitive Landscape And Company Profiles
27.1. Kidney Cancer Drugs Market Competitive Landscape
27.2. Kidney Cancer Drugs Market Company Profiles
27.2.1. Bayer AG
27.2.1.1. Overview
27.2.1.2. Products and Services
27.2.1.3. Strategy
27.2.1.4. Financial Performance
27.2.2. Pfizer Inc
27.2.2.1. Overview
27.2.2.2. Products and Services
27.2.2.3. Strategy
27.2.2.4. Financial Performance
27.2.3. Novartis International AG
27.2.3.1. Overview
27.2.3.2. Products and Services
27.2.3.3. Strategy
27.2.3.4. Financial Performance
27.2.4. Exelixis, Inc
27.2.4.1. Overview
27.2.4.2. Products and Services
27.2.4.3. Strategy
27.2.4.4. Financial Performance
27.2.5. F. Hoffmann-La Roche Ag
27.2.5.1. Overview
27.2.5.2. Products and Services
27.2.5.3. Strategy
27.2.5.4. Financial Performance

28. Kidney Cancer Drugs Pipeline Analysis

29. Key Mergers And Acquisitions In The Kidney Cancer Drugs Market

30. Kidney Cancer Drugs Market Future Outlook and Potential Analysis

31. Appendix
31.1. Abbreviations
31.2. Currencies
31.3. Research Inquiries
31.4. About the Publisher
31.5. Copyright And Disclaimer
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Abbott Laboratories
  • Aveo Pharmaceuticals
  • Eisai
  • Glaxosmithkline Plc
  • NeoGenomics Laboratories
  • Prometheus Laboratories
  • MORE
Major players in the kidney cancer drugs market are Bayer AG, Pfizer Inc., Novartis International AG, Exelixis, Inc., and F. Hoffmann-La Roche Ag.

The global kidney cancer drugs market is expected to decline from $3.3 billion in 2020 to $3.29 billion in 2021 at a compound annual growth rate (CAGR) of -0.3%. The slow decline is mainly due to the outbreak of COVID-19 that has led to deferment of immunocompromised treatments. The market is expected to reach $3.6 billion in 2025 at a CAGR of 2.3%.

The kidney cancer drugs market consists of sales of kidney cancer drugs. It includes immunotherapy, chemotherapy and targeted therapy

The market covered in this report is segmented by type into renal cell carcinoma (RCC), transitional cell carcinoma (TCC) or urothelial cell carcinoma (UCC); by product into nexavar (sorafenib), sutent (sunitinib), afinitor (everolimus), votrient (pazopanib), avastin (bevacizumab), inlyta (axitinib), torisel (temsirolimus), proleukin (aldesleukin), others; by end users into hospitals, clinics, research center, others.

The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Increasing use of biologics and targeted therapies acts as a restraint for the kidney cancer drugs market. When kidney cancer is spread to other organs, targeted therapies are used to control kidney cancer where chemical drugs are ineffective. Also, targeted drugs are used post kidney cancer surgery to prevent re-occurrence of kidney cancer. Conventional chemical drugs cannot be used in the same way. Also, targeted therapies for kidney cancer has illustrated higher efficiency than normal chemical drug-based chemotherapy in random clinical trials. In a study conducted by Pfizer, using targeted therapy had more chances of tumor shrinkage than using chemical drugs. Targeted drug, axitinib and Pembrolizumab are being used to treat stage IV kidney cancer which specially attacks the spreading points of cancer. Thus, pharmaceutical industry is embracing the targeted therapies because of the above-mentioned benefits. Therefore, hindering the growth of the kidney cancer drugs market.

Use of combination therapy is trending in the kidney (renal) cancer drugs market. Combination therapy combines the effects of various drugs thereby reducing the likelihood of cancer resistant cells from developing. The improved understanding about renal cancer causes and effects has led to the discovery of combination therapy. Under this treatment the drugs from vascular endothelial growth factor (VEGF), which stimulate the protein in the blood are combined with inhibitors of mammalian target of rapamycin (mTor), which helps promote cellular biogenesis. According to a study conducted by National cancer institute (NIH) in 2019, the combination treatment leads to better outcomes in the patients suffering from advanced kidney cancer. In April 2019, Merck attained food and drug administration (FDA) approval to combine their drug Pembrolizumab, which enhances the patients’ immune system along with Pfizer’s drug Axitinib, which prevents the spread of renal cancer, this combination of drugs can help increase the pace of the patients’ recovery in advanced kidney cancer.

In April 2019, Bristol-Myers Squibb Company, an American pharmaceutical company got the approval to acquire Celgene corporation for $74 billion. The transaction is expected to create a leading specialty company which would address the needs of patients with cancer, inflammatory and immunologic disease and cardiovascular disease through high-value innovative medicines and leading scientific capabilities. Celgene corporation, a company that develops medicines for cancer and inflammatory disorders, was founded in 1996 and has its headquarters in the USA.

Rise in incidence of renal cancer acts as one of the major drivers of the kidney cancer drugs market. Change in lifestyle of people, consumption of tobacco and unhealthy diet are some factors which contribute to the growth of these renal cancer cells. According to American Cancer Society Report, an estimated 73,750 new cases of kidney (renal) cancer were diagnosed in the US in 2020. Thus, driving the growth of the kidney cancer drugs market.

The kidney cancer drugs market is governed by regulatory framework of agencies such as Food and Administration Agency (FDA) and American Society of Clinical Oncology (ASCO). FDA's recommendation for kidney cancer drugs industry in the form of guidelines are mentioned within the CFR 's (Code for Federal Regulations) title number 21 under part 312, that contains sub-parts from sub part 'A' to sub part 'I'. The sub-part 'E' deals with the procedures designed to push the development, evaluation, and marketing of drugs related to therapies aimed to treat persons with life-threatening and illnesses such as kidney cancer. The sub part 'E' also includes guidelines for the monitoring and evaluation of clinical trials of kidney cancer drugs and other cancer drugs by agency officials to determine whether new treatments are safe and effective, or better than existing treatments. All companies operating in kidney cancer drugs industry are required to abide to the regulations under FDA.

The countries covered in the market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.
Note: Product cover images may vary from those shown
  • Bayer AG
  • Pfizer Inc
  • Novartis International AG
  • Exelixis Inc
  • F. Hoffmann-La Roche Ag
  • Genentech Inc.
  • Glaxosmithkline Plc
  • Active Biotech
  • Amgen
  • Thermo Fisher Scientific Inc
  • Bristol-Myers Squibb
  • Eisai
  • Roche
  • Cipla Limited
  • Onyx
  • Abbott Laboratories
  • Aveo Pharmaceuticals
  • Immatics Biotechnologies
  • Prometheus Laboratories
  • Argos Therapeutics
  • Myriad Genetics Inc
  • NeoGenomics Laboratories
  • NanoString Technologies Inc
  • Sysmex Corporation
  • Rosetta Genomics
  • Illumina Inc
  • Quest Diagnostics Incorporated
Note: Product cover images may vary from those shown

Loading
LOADING...

Adroll
adroll